Article thumbnail

Laforin, the most common protein mutated in Lafora disease, regulates autophagy

By Carmen Aguado, Sovan Sarkar, Viktor I. Korolchuk, Olga Criado, Santiago Vernia, Patricia Boya, Pascual Sanz, Santiago Rodríguez de Córdoba, Erwin Knecht and David C. Rubinsztein


Lafora disease (LD) is an autosomal recessive, progressive myoclonus epilepsy, which is characterized by the accumulation of polyglucosan inclusion bodies, called Lafora bodies, in the cytoplasm of cells in the central nervous system and in many other organs. However, it is unclear at the moment whether Lafora bodies are the cause of the disease, or whether they are secondary consequences of a primary metabolic alteration. Here we describe that the major genetic lesion that causes LD, loss-of-function of the protein laforin, impairs autophagy. This phenomenon is confirmed in cell lines from human patients, mouse embryonic fibroblasts from laforin knockout mice and in tissues from such mice. Conversely, laforin expression stimulates autophagy. Laforin regulates autophagy via the mammalian target of rapamycin kinase-dependent pathway. The changes in autophagy mediated by laforin regulate the accumulation of diverse autophagy substrates and would be predicted to impact on the Lafora body accumulation and the cell stress seen in this disease that may eventually contribute to cell death

Topics: Articles
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A molecular investigation of true dominance in Huntington’s disease.
  2. (1999). A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).
  3. (2007). A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori’s disease.
  4. (2009). A role for ubiquitin in selective autophagy.
  5. (2008). Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
  6. (2007). Advances in Lafora progressive myoclonus epilepsy.
  7. (2009). Autophagic clearance of aggregate-prone proteins associated with neurodegeneration.
  8. (2009). Autophagy in skeletal muscle: implications for Pompe disease.
  9. (2009). Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates.
  10. (1911). Beitrag zur Histopathologie der myoklonischen Epilepsie.
  11. (1975). Biochemical studies on tissues from a patient with Lafora disease.
  12. (2003). Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions.
  13. (2006). Dimerization of laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
  14. (2008). Does bafilomycin A1 block the fusion of autophagosomes with lysosomes?
  15. (2006). Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
  16. (2002). Genotype-phenotype correlations for EPM2A mutations in Lafora’s progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
  17. (2006). Glycogen autophagy in glucose homeostasis.
  18. (2005). Glycogen autophagy in the liver and heart of newborn rats. The effects of glucagon, adrenalin or rapamycin.
  19. (2007). How shall I eat thee?
  20. (2008). Huntington’s disease: degradation of mutant huntingtin by autophagy.
  21. (2009). Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
  22. (2009). In search of an ‘autophagomometer’.
  23. (2005). Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
  24. (2009). Intracellular protein degradation in mammalian cells: recent developments.
  25. (2007). Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
  26. (2006). Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
  27. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
  28. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice.
  29. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
  30. (2005). Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy.
  31. (2008). Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).
  32. (2009). Mammalian macroautophagy at a glance.
  33. (2007). Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy.
  34. (1998). Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.
  35. (2003). Mutations in NHLRC1 cause progressive myoclonus epilepsy.
  36. (2008). Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway.
  37. (2006). p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery.
  38. (1967). Progressive familial myoclonic epilepsy with Lafora bodies. Electron microscopic and histochemical study of a cerebral biopsy.
  39. (2007). Progressive myoclonic epilepsy: a clinical, electrophysiological and pathological study from South India.
  40. (2004). Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus.
  41. (2006). Rapamycin pre-treatment protects against apoptosis.
  42. (2004). Regulation and role of autophagy in mammalian cells.
  43. (2008). Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway.
  44. (2007). Regulation of various proteolytic pathways by insulin and amino acids in human fibroblasts.
  45. (2006). Signalling and autophagy regulation in health, aging and disease.
  46. (2007). Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models.
  47. (1968). Studies in myoclonus epilepsy (Lafora body form). Isolation and preliminary characterization of Lafora bodies in two cases.
  48. (2009). Tau Human Molecular Genetics,
  49. (2007). The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease.
  50. (2004). The role of autophagy during the early neonatal starvation period.